Clinical Trial

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-25; most recent amendment 2025-09-23.
Status change: Not Yet Recruiting → Recruiting 2025-09-23
Trial Details
NCT Number NCT07050186
Lead Sponsor Northwestern University
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Enrollment 15 participants
Start Date 2025-08-15
Primary Completion 2030-11-20 (estimated)
Study Completion 2035-11-20 (estimated)
Updated on ClinicalTrials.gov 2025-09-29